Table 1.
Demographical and clinical information of the 90 enrolled subjects at T3.
| Characteristics | Rheumatoid arthritis-patients | Health care workers | P-value | |
|---|---|---|---|---|
| N (%) | 52 (57.8) | 38 (42.2) | ||
| Age median (IQR) | 61 (55-69) | 44 (30-51) | <0.0001a | |
| Female N (%) | 43 (82.7) | 29 (76.3) | 0.594b | |
| Origin N (%) | West Europe | 44 (84.6) | 37 (97.4) | 0.135b |
| East Europe | 5 (9.6) | 0 (0) | ||
| Asia | 1 (1.9) | 1 (2.6) | ||
| South America | 2 (3.9) | 0 (0) | ||
| Rheumatologic treatment N (%) | TNF-α inhibitors | 7 (13.4) | - | |
| IL-6 inhibitors +/-DMARDs/CSs | 13 (25) | - | ||
| CTLA-4-Ig +/-DMARDs/CSs | 12 (23.1) | - | ||
| DMARDs +/- CSs | 12 (23.1) | - | ||
| JAK inhibitors +/-DMARDs/CSs | 8 (15.4) | - | ||
| Disease activity median (IQR) | DAS28crp | 3.2 (2.3-3.5) | - | |
| Lymphocytes count N (%) | 42 (80.8) | 0 (0) | ||
| Lymphocytes count N (%)Median x 103/µl (IQR) | TNF-α inhibitors | 6 (14.3)2.5 (2.0-3.3) | - | 0.174c |
| IL-6 inhibitors +/-DMARDs/CSs | 11 (26.2)1.8 (1.3-2.3) | - | ||
| CTLA-4-Ig +/-DMARDs/CSs | 12 (28.6)2.2 (1.8-2.8) | - | ||
| DMARDs +/- CSs | 7 (16.7)2.1 (1.4-2.3) | - | ||
| JAK inhibitors +/-DMARDs/CSs | 6 (14.3)1.9 (1.3-2.5) | - | ||
| Therapy, median years (IQR) | 5.4 (2.4-8.4)d | - | ||
| TNF-α inhibitors | 2.9 (1.8-12) | - | ||
| IL-6 inhibitors +/-DMARDs/CSs | 6.1 (5.2-7.8) | - | ||
| CTLA-4-Ig +/-DMARDs/CSs | 7.4 (2.3-10.9) | - | 0.250c | |
| DMARDs +/- CSs | 5.4 (2.5-6.6) | - | ||
| JAK inhibitors +/-DMARDs/CSs | 3.4 (1.1-4.2) | - | ||
Abbreviations: CSs, corticosteroids; CTLA-4, Cytotoxic T-lymphocyte antigen 4; DAS28crp, disease activity score 28 based on C-reactive protein; DMARDs, disease-modifying anti-rheumatic drugs; Ig, immunoglobulin; IL, interleukin; IQR, interquartile range; JAK, Janus Kinase; N, number; TNF, tumor necrosis factor.
a
Mann-Whitney U-statistic test; bChi-square test; cKruskal-Wallis test; davailable only for 39/52 subjects.